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Abstract Bartter syndrome with sensorineural deafness
(type IV Bartter syndrome) is a subtype of this tubular
disease, and is due to mutations in the BSND gene. Out of a
population of 92 patients with Bartter syndrome, five
suffered from mild to severe hypoacusia and were selected
for mutational screening. A homozygous mutation in the
BSND gene was found in two female patients. The first
patient was found to have a substitution in intron 1 donor
splice site at position +5 (c.420+5G>C), whereas the
second patient has a homozygous 3G>A substitution
leading to the loss of the start codon for the translation of
the BSND mRNA. The clinical courses of these two
patients were remarkable for severe polyhydramnios,
massive renal salt and water wasting, severe neonatal
hypotonia, poor growth and unresponsiveness to prostag-
landin inhibitors. The diuretic responses to furosemide and
to hydrochlorothiazide were tested under KCl supplemen-
tation in one patient. A lack of response to both drugs
suggested that inhibition of NaCl reabsorption in type IV
Bartter syndrome is not restricted to the thick ascending
limb of Henle. In one patient, a combined therapy with
indomethacin and captopril was needed to discontinue
intravenous fluids and improve weight gain.
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Introduction
Bartter syndrome (BS) identifies a group of closely related
hereditary salt-losing renal tubular disorders characterized
by hypokalemic metabolic alkalosis. To date, five different
genes involved in NaCl reabsorption in the thick ascending
limb of Henle have been identified [1].
Infantile BS with sensorineural deafness, also referred as
type IV BS (OMIM 602522), is in most cases due to
autosomal recessive mutations in the BSND gene, located
on chromosome 1p31 [2–4]. The BSND gene encodes for
the Barttin protein, which acts as an essential subunit of the
ClC-Ka and ClC-Kb chloride channels. In the kidney,
Barttin is expressed in tubular segments spanning from the
thick ascending limb to cortical collecting ducts, whereas
in the inner ear, it is expressed in potassium-secreting
epithelial cells [5].
Most mutations of the BSND gene cause a severe form of
neonatal BS which is characterized, in addition to deafness,
by markedly severe tubular salt wasting, frequent evolution
to chronic renal failure, absence of overt medullary
nephrocalcinosis and resistance to indomethacin therapy
[6]. Altogether, BSND mutations are responsible for a
minority of the cases of BS. To date, only a few mutations
have been reported [2].
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All BS patients with hearing impairment were selected in
order to screen for mutations in the BSND gene. A hearing
test was not performed for all patients; only those that had a
neonatal form of BS or had clinical evidence of hearing
impairment were tested.
Genetic analysis
DNAwas extracted from blood samples using the QIAamp
DNA blood Minikit (QIAGEN S.p.A., Milano, Italy).
Exons 1–4 of the BSND gene were amplified by polymer-
ase chain reaction (PCR) using previously published
primer sequences and amplification conditions [2]. Direct
sequencing was performed with the Big Dye Terminator kit
(Beckman Coulter, Brea, CA, USA) and resolved by
capillary electrophoresis with a CEQ2000XL DNA Anal-
ysis System (Beckman Coulter). Restriction fragment
length polymorphism was performed at 37 °C for 3 h
with the AluI restriction enzyme (Fermentas, Burlington,
Ontario, Canada) on PCR fragments amplifying exon 1
flanked by 35 additional bases. The digested fragments
were resolved on a 2% agarose gel.
Hydrochlorothiazide and furosemide testing
Furosemide (0.5 mg/kg) or hydrochlorothiazide (0.5 mg/
kg) [7] were given per os on different days, 30 minutes
after KCl supplementation. To avoid any worsening of
hypokalemia, intravenous KCl infusion was given through
an existing intravenous line. Two baseline urine samples
were collected at one-hour intervals before the test, and one
and two hours after diuretic administration. Serum K was
monitored after two and four hours. Written informed
consent was obtained.
Fig. 1 a Fluid balance, therapy
and weight gain of patient 1.
b Renal response to furosemide
and to hydrochlorothiazide in
patient 1 (BSND), in one patient
with Gitelman syndrome and
one patient with Bartter syn-
drome. See text for details
Urinary Na, Cl and creatinine were measured in all
collected samples. The [NaCl]/creatinine ratio (mmol/
mmol of creatinine) was averaged in the two baseline
samples and in the two test samples. Results were




Out of a cohort of 92 patients with BS followed in Milano
and Rome, five patients had evidence of hearing impair-
ment and were screened for BSND mutations. Mutations
were found in two patients. One of the three patients
without detectable mutations was subsequently diagnosed
with a mitochondria cytopathy. The second patient devel-
oped a severe psychotic disorder associated with her BS
over time, and the third patient presented with only mild
hearing impairment, which may have been secondary to
drug toxicity during the neonatal period. Genetic testing for
other BS genes is underway.
One patient (patient 1) was found to have a novel
homozygous mutation in the intron 1 donor splice site at
position +5 (c.420+5G>C). According to the “Automated
Splice Site Analyses program” (http://splice.cmh.edu/), this
mutation is predicted to cause an 8.3-fold decrease in the
binding site strength, resulting in a complete loss of the
splice site. Unfortunately, amplification of BSND mRNA
from shedded renal tubular cells recovered from urine
samples was unsuccessful, whether attempted from the
patient’s urine or from the urine of control subjects.
As this mutation introduces a restriction site for the AluI
enzyme, screening for a potential polymorphic change was
achieved by restriction fragment length polymorphism. No
mutation was found in 200 chromosomes from normal
Italian individuals. Both parents were found to be hetero-
zygous carriers.
The second patient (patient 2) was found to have a
homozygous 3G>A substitution leading to the loss of the
start codon (ATG mutated into ATA) of the BSND mRNA.
Both parents were found to be heterozygous carriers.
In both cases the parents were unrelated, but they came
from families from the same small province in northern or
southern Italy.
Clinical evolution
A. Patient 1 was born prematurely at 33 weeks of gestation
with a birth weight of 2.450 kg after a pregnancy
complicated by severe polyhydramnios. Soon after birth,
the child developed severe polyuria associated with marked
hypokalemic alkalosis. She was transferred to our unit at
one month of age. Her physical examination was
remarkable for prominent axial hypotonia with spontane-
ous hyperextension of the neck. Initial serum blood tests
showed the following results: creatinine 45.1 μmol/L, K
2.8 mmol/L, Na 132 mmol/L, Mg 0.62 mmol/L, HCO3
38 mmol/L, BE +15 mmol/L, aldosterone >4.15 nmol/L,
renin >7.58 pmol/L. Urinary calcium/creatinine ratio was
within the normal range (1.7–2.3 mM/mM). The renal
ultrasound showed diffusely hyperechogenic kidneys
without signs of nephrocalcinosis. Hearing tests showed
an absence of evoked response to stimulation up to 120 dB.
Figure 1a summarises the fluid balance, weight gain and
response to therapy of patient 1 during the first few weeks
after admission. Primary treatment included supplementa-
tion with fluids and electrolytes to match urinary losses,
both intravenously and per os through a nasogastric feeding
tube. Mean KCl and NaCl requirements were 27 and
34 mmol/kg/day respectively, while fluid intake averaged
526 ml/kg/day during the first two weeks.
Indomethacin treatment was immediately initiated using
doses of up to 5 mg/kg/day, without obtaining significant
clinical and biochemical improvement. No improvement
was observed after additional therapy with the cyclooxy-
genase-2 inhibitor nimesulide [8] at a dose of 20 mg/kg/day
either. Following the hypothesis that indomethacin was not
efficiently reabsorbed by the gastrointestinal tract, it was
also given intravenously for six days without any notice-
able benefit.
Based on the resistance to prostaglandin inhibitors, the
indomethacin dosage was lowered to 3 mg/kg/day and
captopril was initiated at a dosage of 0.35 mg/kg/day. This
treatment regimen was tolerated well and considerably
improved the clinical course. The average weight gain
increased from 9 to 16 g/day. Fluid requirements decreased
from 530±66 to 473±44 ml/kg/day and urine output
decreased from 479±63 to 430±40 ml/kg/day. Most
noticeably, intravenous fluids could be stopped, which
had been attempted unsuccessfully twice under the
previous treatment regimens. The mean serum creatinine
increased from 47.7±5.3 to 55.7±9.7 μmol/L (p<0.02).
Systolic blood pressure decreased from 74±13 to 66±
7 mmHg (p<0.01) and diastolic blood pressure decreased
from 45±11 to 38±7 mmHg (p<0.01). KCl and NaCl
supplementation could only be marginally decreased. No
improvement was observed in the control of the metabolic
alkalosis. The urinary calcium/creatinine ratio increased
rapidly to 2.55–4.24 mM/mM after initiation of NaCl
supplementation.
At one year of age, the follow-up renal ultrasound did
not show any evidence of nephrocalcinosis. Body weight
was −4.2 SD and height was −4.6 SD. Axial hypotonia had
improved considerably. Fluid requirement was approxi-
mately 240 ml/kg/day. Serum creatinine was 71 μmol/L
(estimated GFR=35 ml/min/1.73 m2, according to the
Schwartz formula).
At the last follow-up at the age of 26 months, the patient
had persistent chronic renal failure (estimated GFR=56 ml/
min/1.73 m2, according to the Schwartz formula). Somatic
growth had improved considerably with continuous noc-
turnal enteral feeding and treatment with recombinant
human growth hormone. Both weight and height have
reached the third percentile. Proteinuria and hematuria
were both absent. Blood pressure was 84/52 mmHg.
B. Patient 2 was born at 37 weeks of gestation with a
birth weight of 2.520 kg after a pregnancy complicated by
severe polyhydramnios. The postnatal physical examina-
tion was remarkable for prominent axial hypotonia. At
three months of age the child was admitted to a local
hospital for severe failure to thrive and was found to have
hypokalemia (2.9–3.5 mmol/L), metabolic alkalosis
(HCO3 33.5 mmol/L, BE +8.5 mmol/L), mild hyperrenin-
emia (1.80 pmol/L) and normal aldosterone plasma level
(0.454 nmol/L). FeNa was 2.1% and FeCl was 10.2%.
Renal ultrasound showed diffuse renal hyperechogenicity,
but no signs of nephrocalcinosis. Urinary calcium/creati-
nine excretion was normal (1.50 mM/mM). Arterial blood
pressure was 68–57/42–25 mmHg. Hearing tests at
three months of age demonstrated severe hypoacusia with
an absence of evoked response to stimulation at 120 dB.
Treatment has included indomethacin (2.8 mg/kg/day),
and KCl and NaCl supplementation (both at a dosage of
3.5 mmol/kg/day). Indomethacin treatment was not
followed by any significant improvement in the clinical
picture. In particular, no significant improvement in growth
velocity was obtained until continuous enteral feeding was
started at the age of eight months, resulting in a weight gain
of 900 g in five weeks.
At the last follow-up at 19 months of age, the patient
weight and height were both at −3.5 SD. Serum creatinine
was normalized 42.4 μmol/L (estimated GFR 81 ml/
min/1.73 m2 according to the Schwartz formula), after
having always been just below the lower limit for the age for
the first 18 months of life. The patients never had proteinuria
or hematuria. Serum potassium levels continue to be quite
low (2.5 mmol/L) despite therapy. A recent follow-up
ultrasound did not show signs of nephrocalcinosis.
Diuretic testing
In view of the large urinary electrolyte losses of patient 1
and of his unresponsiveness to conventional pharmacolog-
ical treatment, we have hypothesized that inhibition of
NaCl reabsorption was not restricted to the thick ascending
limb of Henle. Therefore, renal response to furosemide and
to hydrochlorothiazide was tested (Fig. 1b). As shown, no
response was obtained with these drugs. In comparison, the
results of three tests performed previously are reported.
These tests were performed in older patients (age range 10–
14 years) presenting with a difficult differential diagnosis
between Gitelman syndrome and type III BS. Two of these
patients had a good response to hydrochlorothiazide but
none to furosemide, suggesting a diagnosis of BS, whereas
one patient had the opposite pattern of response, suggesting
a diagnosis of Gitelman syndrome.
Discussion
We have reported on two new cases of neonatal type IV
Bartter syndrome. These cases represent a minority of our
total cases of BS (approximately 2%). Both patients
demonstrated a typical clinical history of neonatal type
IV BS [6]. Pregnancy was complicated by severe polyhy-
dramnios and the post-natal course was characterized by
massive renal salt and water losses, poor response to
prostaglandins inhibitors, severe hypotonia and poor
growth.
The BSND gene mutation of patient 2 (3G>A) has been
reported previously [2]. It is expected to cause a complete
loss of function, as it abolishes the start codon for initiation
of translation. The mutation of patient 1 (c.420+5G>C) is
located in intron 1, five bases into the natural splicing site.
The functional consequences of this substitution cannot be
indisputably proven. Nonetheless, the typical clinical
picture of type IV BS, the homozygosity of the mutation,
the evidence that it does not correspond to a polymorphic
change and the theoretical calculation predicting severe
weakening of the binding site strength strongly suggest that
this mutation is likely to severely alter the Barttin protein
function.
Mutations in the BSND gene or deletions encompassing
the ClCNKB and ClCNKA genes have been reported to be
associated with progression of chronic renal failure, which
is an uncommon complication for other types of BS [2, 9,
10]. Other authors have not confirmed these findings [6]. It
has been proposed that decline in renal function may also
be secondary to the nephrotoxicity of nonsteroidal anti-
inflammatory agents, in particular indomethacin [11]. A
recent report, however, indicates that prostaglandin
inhibitors are generally tolerated well by patients with
hereditary hypokalemic salt-losing tubulopathies, without
evidence of impaired renal function after 10–15 years of
treatment [12].
Whereas renal function was normalized at 18 months of
age in patient 2, after it had constantly been just below the
lower limit of normal, patient 1 demonstrated persistent
chronic renal failure at her last follow-up at 26 months of
age. In our view, in patient 1 it is not possible to distinguish
between renal function impairment secondary to combined
captopril and indomethacin therapy and increased serum
creatinine secondary to structural renal changes related to
the BS. As in other type IV BS cases, these two patients
were remarkable for the severity of their axial hypotonia
and for the magnitude of their renal salt wasting.
As previously reported, tubular dysfunction was not
improved substantially by indomethacin and/or nimesulide
treatment [10, 11]. Lack of response to indomethacin could
not be attributed to decreased intestinal reabsorption in
patient 1, as it was not improved by i.v. administration of
the drug.
Also, higher dosages or a combination of both agents did
not produce any substantial benefits. Accordingly, Re-
inalter et al. have previously documented a lack of a
decrease in urinary prostaglandin excretion after indo-
methacin treatment in patients with type IV BS [12].
Hypothetically, chloride fluxes, which activate the macula
densa and thereby modulate COX2 activity and renin
secretion [13], may require normal Barttin expression.
Patient 1 improved only after a combined therapy with
indomethacin and captopril, an approach which has been
used to control severe congenital nephrosis [11] and which
may have exerted its beneficial effects primarily by
decreasing the glomerular filtration rate.
The results of the diuretic tests may provide additional
insight into the pathophysiology of type IV BS. Unlike the
ClC-Kb channel (mutated in type III BS), the expression
of the Barttin protein, which acts as a functional subunit of
ClC-Kb, is not restricted to the thick ascending limb of
Henle [14]. Accordingly, diuretic tests in patient 1 showed
an absence of response to both furosemide and hydrochlo-
rothiazide. Inhibition of NaCl reabsorption therefore also
appears to extend to distal segments of the nephron, which
may explains the magnitude of tubular NaCl losses in type
IV BS. In addition, these results provide a reasonable
explanation for the lack of substantial hypercalciuria and
protection against the development of overt nephrocalci-
nosis in these patients. In fact, inhibition of NaCl
reabsorption in classic BS engenders hypercalciuria,
whereas decreased NaCl reabsorption in the distal convo-
luted tubule is associated with hypocalciuria in Gitelman
syndrome or after thiazide treatment [15]. In type IV BS
these opposite effects may coexist, thus limiting the
magnitude of urine calcium excretion despite massive
urinary NaCl losses.
It is important to note, however, that the results reported
for furosemide and hydrochlorothiazide tests were obtained
from only one patient. Therefore, although they appear to
be coherent with the known pattern of expression of the
Barttin protein in the renal tubule, they should be
interpreted with caution and need to be confirmed by
other investigators.
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